首页> 美国卫生研究院文献>other >Prostate Cancer Gender Identity and Testosterone Replacement Therapy in Klinefelter Syndrome: A Case Report and Literature Review
【2h】

Prostate Cancer Gender Identity and Testosterone Replacement Therapy in Klinefelter Syndrome: A Case Report and Literature Review

机译:Klinefelter综合征的前列腺癌性别认同和睾丸激素替代疗法:病例报告和文献综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Klinefelter syndrome (KS), karyotype 47, XXY, is a common cause of hypogonadism in males. Patients with this condition often experience symptoms of gonadal failure, which can precipitate gender identity challenges. Treatment with testosterone replacement therapy (TRT) can combat these symptoms by improving sexual function, muscle mass, bone health, and virilization, thereby enhancing the quality of life (QOL). Although TRT is often employed in patients with KS, there is a concern that the application of exogenous testosterone may increase the risk of prostate adenocarcinoma development and progression. We report the case of a 58-year-old male with KS who is also diagnosed with prostate adenocarcinoma and wished to remain on TRT post-radiation therapy in support of his gender identity and QOL. We describe the challenges this patient faced when balancing a rising prostate-specific antigen level and risk of cancer recurrence with his QOL.
机译:Klinefelter综合征(KS),核型47,XXY,是男性性腺功能低下的常见原因。患有这种疾病的患者经常会出现性腺衰竭的症状,这可能会加剧性别认同的挑战。睾丸激素替代疗法(TRT)可以通过改善性功能,肌肉质量,骨骼健康和男性化来对抗这些症状,从而提高生活质量(QOL)。尽管KS患者经常使用TRT,但存在的担忧是外源性睾丸激素的使用可能会增加前列腺腺癌发展和进展的风险。我们报道了一例58岁的KS男性患者,他也被诊断患有前列腺腺癌,并希望继续接受TRT放射治疗以支持其性别认同和QOL。我们描述了该患者在通过QOL平衡前列腺特异性抗原水平升高和癌症复发风险时面临的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号